PT  - JOURNAL ARTICLE
AU  - Sara Hermoso De Mendoza Aristegui
AU  - Luisa Ramón
AU  - Carla Suárez
AU  - Carlos Bravo
AU  - Cristina Berastegui
AU  - Jaume Sauleda
AU  - Ernest Sala
AU  - Francisco Javier Verdú
TI  - Usefulness of lactate dehydrogenase and serum C-reactive protein in the follow-up of patients with lung transplantation
AID  - 10.1183/13993003.congress-2020.4730
DP  - 2020 Sep 07
TA  - European Respiratory Journal
PG  - 4730
VI  - 56
IP  - suppl 64
4099  - http://erj.ersjournals.com/content/56/suppl_64/4730.short
4100  - http://erj.ersjournals.com/content/56/suppl_64/4730.full
SO  - Eur Respir J2020 Sep 07; 56
AB  - Introduction: Lactate dehydrogenase (LDH) and serum C-reactive protein (CRP) are biomarkers of inflammation with prognostic value. Its role in the follow-up of patients with lung transplantation (LT) is poorly knownMethod: Serum LDH and CRP are useful in the clinical follow-up of these patientsObjetive: To evaluate the association of serum LDH and CPR values with chronic complications and mortality in patients with LTMethods: Patients of our LT outpatient clinic shared with the LT unit of Valle Hebrón Hospital of Barcelona (2014-2019). In all visits, clinical history, physical examination, spirometry, chest x-ray and blood tests that included: LDH and CPR, drug levels and cytomegalovirus (CMV) determinationResults: We studied 31patients (19M/12W, 52±2 years (X±SEM), FEV1 62±4%, FVC 71±4%, FEV1/FVC 71±2%, 27 bilateral, 3 unilateral):16 COPD, 9 ILD, 4 cystic fibrosis and others (2). All of them received immunosuppressive treatment, corticosteroids and antibiotic prophylaxis. During this period 7 patients died, 19 had respiratory infection, 8 CMV infection, 23 chronic renal failure and 14 patients were admitted (infection or rejection). The LDH and CPR levels at the first visit were 319±27 U/L and 0.8±0.2 mg/dl, respectively. LDH levels between the first and last visit decreased 25±5% in survivors and increased 29±23% in the deceased (p <0.05). In patients with chronic rejection LDH only showed differences in the restrictive allograft syndrome (RAS): increase of 67±37% with RAS and -21±6% without it (p <0.01). There were no differences in CRPConclusions: Changes in LDH values during the follow-up of these patients are associated with RAS and worse prognosisFootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 4730.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).